Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

Author：

E-ISSN： 1791-2431|35|1|454-462

ISSN： 1021-335X

Source： Oncology Reports, Vol.35, Iss.1, 2016-01, pp. : 454-462

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HER2-Positive Breast Cancer: Incidence, Prognosis, and Treatment Options

By Estévez L.G.

American Journal of Cancer, Vol. 2, Iss. 3, 2003-01 ,pp. : 169-179

Adis International

Access to resources Recommend Favorite

Diagnosis and prognosis of breast and ovarian cancer

By Thulesius Hans Lindgren Anna Olsson Håkan Håkansson Anders

Acta Oncologica, Vol. 43, Iss. 2, 2004-03 ,pp. : 175-181

Informa Healthcare

Access to resources Recommend Favorite

Identification of a metabolic and canonical biomarker signature in Mexican HR+/HER2-, triple positive and triple-negative breast cancer patients

International Journal of Oncology, Vol. 45, Iss. 6, 2014-01 ,pp. : 2549-2559

Spandidos Publications

Access to resources Recommend Favorite

Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome

By Lobbezoo Dorien Kampen Roel Voogd Adri Dercksen M. den Berkmortel Franchette Smilde Tineke Wouw Agnes Peters Frank Riel Johanna Peters Natascha Boer Maaike Borm George Tjan-Heijnen Vivianne

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 507-514

Springer Publishing Company

Access to resources Recommend Favorite

PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis

By Aleskandarany Mohammed

Breast Cancer Research and Treatment, Vol. 122, Iss. 1, 2010-07 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite